|
|
|
|
|
Collaborations and Studies
Collaborations
To validate the impact of VeraTag™ assays on research and development
of pharmaceutical, biotechnology, and diagnostic products as well as to demonstrate
their potential for individualized therapeutic selection, Monogram has established
agreements with leading companies and collaborations with thought leaders and
biomedical research institutes.
In addition, Monogram has strong ties to prestigious medical research centers and
renowned cancer organizations exploring the use of the VeraTag System in
clinical trials of approved and investigational targeted therapeutics in North
America, Europe and Japan. Our goals are to develop intellectual property, support
publications in peer-reviewed journals, and provide validating clinical data to
support regulatory approvals.
We collaborate with leading research groups, including the following:
- Jules Bordet Institute, Belgium
- Yale University
- Dartmouth-Hitchcock Medical Center
- Mayo Clinic- Rochester, Minnesota
- Mayo Clinic- Jacksonville, Florida
- Penn State Milton S. Hershey Medical Center
- M.D. Anderson Cancer Center
- Stanford University
- University of Southern California/Norris Comprehensive Cancer Center
- Vanderbilt University
- Cedars-Sinai Medical Center/Louis Warschaw Prostate Cancer Center
- Princess Margaret Hospital, Canada
- Tokyo Metropolitan Institute of Medical Science (Rinshoken), Japan
- Aichi Cancer Center, Japan
- Vall D'Hebron University Hospital, Spain
- Osepdale Bellaria, Italy
- Humanitas Instituto Clinico, Italy
- Eastern Cooperative Oncology Group
- National Cancer Center Hospital, Japan
- University Hospital Gasthuisberg, Belgium
- Southwest Oncology Group
- Johns Hopkins University
- University of Colorado Cancer Center
- Dana-Farber Cancer Institute
|
|
|
Studies and Abstracts
To learn more about the development and use of VeraTag technology to help individualize cancer treatment, please refer to the publications below.
VeraTag™ was formerly known as eTag® during development stages.
2008:
- HER2 protein expression and homodimer levels predict response to trastuzumab in centrally tested FISH-positive metastatic breast cancer patients.
A. Lipton, S. Ali, K.Leitzel, W. Koestler, E. Fuchs, J. Weidler, Y. Wu, J. Sperinde, C.Chappey, W. Huang, M. Bates
31st Annual San Antonio Breast Cancer Symposium Abstract #32, ORAL PRESENTATION
- Quantitative HER2 homodimer levels correlate with time to first recurrence in HER2-positive breast cancer patients who did not receive trastuzumab in the adjuvant setting.
M.Bates, J. Sperinde, K.Leitzel, W. Koestler, E. Fuchs, S. Ali, J. Weidler, Y. Wu, C.Chappey, W. Huang, A.Lipton.
31st Annual San Antonio Breast Cancer Symposium Poster #1074
- Quantitative measurements of HER2 expression and HER2 homodimer using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study.
Heikki Joensuu, MD, Jodi Weidler, Pharm D, Yolanda Lie, Thomas Sherwood, MD, PhD, Jeannette Whitcomb, PhD, Mika Leinonen, M.Sci., Petri Bono, MD, Jorma Isola, MD4, Pirkko-Liisa Kellokumpu-Lehtinen, MD, Michael Bates, MD and Weidong Huang, MD, PhD.
31st Annual San Antonio Breast Cancer Symposium Poster #2071
- Proximity-based assays for the detection of activated HER3, HER2/3 heterodimers and HER3/PI3K complexes in FFPE cell line controls and tumors.
A. Mukherjee, X Nguyen, S Williams et al.
31st Annual San Antonio Breast Cancer Symposium Poster #4040
- Measurement of the HER3-PI3K Complex as a Marker of PI3K/Akt Pathway Activation in Formalin Fixed, Paraffin-Embedded Cell Line Models and Breast and Ovarian Tumors using a Novel Proximity Assay
M. Badal, A. Newton, S Williams et al.
American Association for Cancer Research Targeting the PI3-Kinase Pathway in Cancer November 10 -14, 2008 Poster
- Development of novel-proximity based immunoassays for activated HER1, HER2, and HER1-HER2 heterodimers in formalin-fixed, paraffin embedded (FFPE) cells.
Lisa DeFazio Eli, Kristi Frankson, Trang Dao-Pick, Jerry Wallweber, Tam Dang, Rajiv Dua, Laurie Goodman, Gordon Parry, John Winslow
20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #88
- Development of highly quantitative, sensitive, and reproducible assays for the detection of EGFR/HER1 and ErbB3/HER3 in formalin-fixed, paraffin-embedded
Yining Shi, Ali Mukherjee, Jennifer Weston, Jolly Bose, Xuan-Thao Nguyen, Agnes Paquet, Colombe Chappey, Gordon Parry, Laurie J. Goodman
20th EORTC-NCI-AACR symposium on "Molecular targets and Cancer Therapeutics" Geneva, Switzerland, 21-24 October 2008 Poster #103
- Comparison of Central HER-2 Tests with Quantitative HER-2 Expression and HER-2 Homodimer Measurements Using a Novel Proximity Based Assay
W Huang, E Perez et al.
Poster #40, College of American Pathology Meeting 2008
- Total HER2 and HER2 homodimer levels predict response to trastuzumab
K. Leitzel, A. Lipton, et al.
American Society of Clinical Oncology 44th Annual Meeting, Chicago, IL June 2, 2008 Oral Presentation
2007:
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2-HER2 dimerization in a clinic- based cohort of patients with metastatic breast cancer
M. P. Bates, C. Desmedt, J. Sperinde, et al.
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol. 25, (18S), 2007: 10557
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer.
M. Toi, J. Sperinde, W. Huang, et al.
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol. 25, (18S), 2007: 1025
- Patterns of HER-family receptor dimerization in trastuzumab susceptible and trastuzumab resistant cell lines.
R. Dua, P. Nhonthachit, C. Rinehart, et al.
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Vol.25, (18S), 2007
- Quantitative measurements of HER2 expression and HER2:HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment.
W. Huang et al.
30th San Antonio Breast Cancer Symposium ,San Antonio, TX, December 12- 16, 2007. Abstract # 2007
- Characterization of a novel proximity immunoassay for the quantitative determination of HER2 protein expression and HER2 homodimerization in formalin-fixed, paraffin-embedded breast cancer tissue.
Winslow et al.
30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 12- 16, 2007. Abstract 2012
- Development of novel proximity-based immunoassays for the detection of HER heterodimerization in breast cancer cell line lysates and formalin-fixed, paraffin-embedded tissue.
Goodman et al.
30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 12- 16, 2007. Abstract # 2011
- Increased detection of breast cancer markers human epidermal growth factor receptor dimer and downstream signaling proteins utilizing the VeraTag technology with dextran modified antibodies.
Wallweber et al.
30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, December 12- 16, 2007. Abstract # 5002
- Profiling HER-family receptor dimerization in HER2 over-expressing cells that co-express mutated EGFR receptors.
Dua et al.
30th San Antonio Breast Cancer Symposium taking place in San Antonio, TX, from December 12- 16, 2007. Abstract # 4108
2006:
- The ERB family receptor dimerization in glioblastoma--An eTag assay analysis of 23 cases.
M. R. Hameed, L. Sharer, E. Cho, S.
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Vol. 24, (18S), 2006: 1582
2005:
- Effect of Erbitux, Erlotinib, Gefitinib and Rapamycin on the Inhibition of EGFR Dimer Formation and Downstream Signaling Pathways in Different Cancer Cell Lines.
Hossein Salimi-Moosavi, Xueguang Jin, Youssouf Badal et al.
International Conference on Molecular Targets and Cancer Therapeutics, November 14-18, 2005 in Philadelphia. Presentation Number: A127
- Multiplex Detection of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Homodimers and Phosphorylation in Xenografts, Human Tumor Tissues and Formalin-Fixed Paraffin-Embedded (FFPE) Samples from Cell Lines Using the eTag™ Assay System.
J. Sperinde, S. Moore, L. Cao, S. Singh and C. Petropoulos
International Conference on Molecular Targets and Cancer Therapeutics, November 14-18, 2005 in Philadelphia. Presentation Number: B17
- ErbB/HER pathway profiling in formalin-fixed paraffin embedded preclinical xenograft models using multiplexed proximity-based assays.
Rajiv Dua, Yining Shi, Liching Cao et al.
International Conference on Molecular Targets and Cancer Therapeutics, November 14-18, 2005 in Philadelphia. Presentation Number: A121
- Effect of Gefitinib on EGFR Activation in Lung Cancer Cell Lines.
Hossein Salimi-Moosavi, Xueguang Jin, Youssouf Badal et al.
International Conference on Molecular Targets and Cancer Therapeutics, November 14-18, 2005 in Philadelphia. Presentation Number: A124
2004:
- Direct Measurement of Multiple mRNAs in Nerve Growth Factor-Induced PC12 Cells Using Electrophoretic Tags to Monitor Biomarkers of Neuronal Differentiation in 96-Well Format.
Pascale Roux, Isabelle Menguy, Stéphane Soubigou, et al.
ASSAY and Drug Development Technologies, 2(6), (2004) 637-646
- Applications of eTag™ assay platform to systems biology approaches in molecular oncology and toxicology studies.
P.-Y. Chan-Hui, K. Stephens, R.A. Warnock, and S. Singh
Clinical Immunology 111 (2004) 162– 174
|
|
 |
|
